Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated
Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.41
- Author:
Bowen LI
1
;
Jianchao XUE
1
;
Yadong WANG
1
;
Zhicheng HUANG
1
;
Naixin LIANG
1
;
Shanqing LI
1
Author Information
1. Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and
Peking Union Medical College (PUMC), Beijing 100730, China.
- Publication Type:Review
- Keywords:
Antiangiogenic drugs;
Combined modality therapy;
Epidermal growth factor receptor;
Lung neoplasms
- MeSH:
Angiogenesis Inhibitors/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/genetics*;
ErbB Receptors/genetics*;
Humans;
Lung Neoplasms/genetics*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2022;25(8):583-592
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in most cases. EGFR-TKI combined with angiogenesis inhibitors is a treatment scheme being explored to delay the therapeutic resistance, which is called "A+T treatment". Several clinical trials have demonstrated that the A+T treatment can improve the progression free survival (PFS) of the NSCLC patients. However, compared to EGFR-TKI monotherapy, the benefits of the A+T treatment based on different EGFR-TKIs, as well as its safety and exploration prospects are still unclear. Therefore, we reviewed the literature related to all three generations EGFR-TKIs combined with angiogenesis inhibitors, and summarized the mechanism, benefit, safety, optimal target population of A+T treatment.
.
